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Introduction
This article presents the state of pharmacoeconomics
and outcomes research in eight countries in the Asia-
Paciﬁc region: China, Japan, South Korea, Singapore,
Thailand, Pakistan, Malaysia, and India. To provide
a better background, a summary table of the key
attributes of the health-care system is also included
within each of the eight countries. This summary table,
as shown in Table 1, demonstrates a wide variation on
most aspects of the health-care system, insurance pro-
grams, total health expenditures (THEs) per capita, and
drug expenditures per capita among the eight countries.
The range of some of the attributes was as follows:
population: 4.25 million to 1.26 billion; Gross Domes-
tic Product (GDP) in 2004: US $620 to $27,800 per
capita; number of hospital beds per 10,000 popula-
tions: 6.8 to 127.7; number of physicians per 10,000
populations: 3.03 to 21.1; and number of pharmacists
per 10,000 populations: 0.53 to 18.9. The ranges for
health economics data were the following: health
expenditure as percentage of GDP 3.7% to 8.89%;
health expenditure per capita from US $62 to $2096;
drug expenditure per capita from US $7 to $483.8;
drugs as a percentage of total health-care spending from
~8% to 44.1%; and availability of local pharmacoeco-
nomic data from an infancy phase to a better estab-
lished stage.
Nevertheless, there are similarities among these
countries. Western medicine is dominant in all
health-care systems, while traditional medicine is still
practiced in some countries. Drug pricing and reim-
bursement are mostly controlled by the government.
No reference pricing system exists in any of the coun-
tries. Use of pharmacoeconomic data is only required
in South Korea.
This article is organized by country-speciﬁc sections,
within each a description is presented to describe 1)
health-care and ﬁnancing systems; 2) drug use and its
trends in expenditure; 3) drug expendituremanagement
associatedwith the development of pharmacoeconomic
guidelines; and 4) role of pharmacoeconomics and out-
comes research in drug expenditure management.
China
Health-Care System and Health-Care Financial System
Universal coverage of health insurance is the future
direction of health system reform in China. At present,
the urban employees’ medical insurance scheme covers
about 170 million workers, and the new rural coop-
erative medical system (RCMS) covers about 726
million populations in 2451 counties by the end of
2007 [1]. Currently, the yearly premium of RCMS in
most rural areas is set around 50 yuan (RMB) per
insured, in which two-thirds of the contribution is paid
by the central and local government, and is used to
reimburse the partial cost of catastrophic illnesses.
Drug Management and Expenditures
Before the 1990s, under the planning economy, drug
production, distribution, and price setting were totally
controlled by the government. After the 1990s, about
8,000 pharmaceutical companies, 16,000 wholesale,
and 11,600 retail pharmaceutical enterprises have
ﬂourished in China. As a result, price competition and
differentials have occurred in the pharmaceutical
industry and distribution system. The annual growth
rate of pharmaceutical expenditure (11.2%) has
exceeded that of GDP (10.3%).
According to data on national health accounts pub-
lished by the Chinese Ministry of Health, the THE was
866 billion yuan RMB in 2005, which is 4.73% of the
national gross domestic product. Based on these data,
the health expenditure per capita is roughly 662.3
yuan (US $83); and 44.1% of the sum, about 317 yuan
(US $40) per capita, was spent on pharmaceuticals [2].
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The share of China in the global pharmaceutical
market is increasing very rapidly. In 2004, the value of
global pharmaceutical sales was US $9.5 billion, which
was ranked ninth in the global pharmaceutical market.
The annual growth rate of 28% was much higher in
China than the average growth rate of 9% in the
world.
Pharmacoeconomics and Outcomes
Research Guidelines
Although pharmacoeconomics is a newly developed
discipline in China, the principles of pharmacoeco-
nomics have been widely noted in health economics,
clinical epidemiology, evidence-based medicine, and
health technology assessment (HTA). Many health
professionals have applied pharmacoeconomic evalu-
ation methods into clinical trials in the phase II, III,
and IV stages. Pharmacoeconomic research ﬁndings
have been applied occasionally in the ﬁeld of drug
price policy, essential drug (ED) listing for reimburse-
ment purpose, drug marketing, and rational use of
drug. In addition, pharmacoeconomics has also been
increasingly applied in the areas of disease burden, cost
analysis, cost-effectiveness, and economic evaluation.
A recent search shows 506 pharmacoeconomic articles
published in 126 journals, and 2034 pharmacoepide-
miology articles published in 43 journals between
1993 and 2002, respectively. In 2006, the ﬁrst China
Journal of Pharmaceutical Economics was published
with the mission to promote the application of phar-
macoeconomics in the management of drug expendi-
tures, health insurance, and rational use of drugs.
To better understand the scope of pharmacoeco-
nomic research in China, a systematic review of 380
pharmacoeconomics and outcomes research articles
retrieved from the Chinese journal database and litera-
ture published before 2003 was conducted recently [3].
The retrieved articles were evaluated according to
study design, comparator selection, cost, effectiveness
measurement, and economic evaluation method. From
the study design, 42% of the articles were prospective
studies, while 28% were retrospective studies; 25%
were literature reviews, and 5% were of a mixed study
design.
Regarding the methodology used in the published
studies, 75% of the publications applied cost-
effectiveness analysis, followed by cost-minimization
analysis (12%). Less than 5% of the publications used
cost-utilization analysis. Cost analyses were calculated
from different perspectives, e.g., patient, hospital,
health insurance, or government. In most of the litera-
ture (44.4%), direct medical cost was used when con-
ducting cost analysis, followed by drug expenditure
cost (24.2%), and by both direct and indirect costs
(23.1%). Only 4.6% of the publications considered
social costs. Markov model was rarely used in these
publications because of lack of parameters from clini-
cal and epidemiological studies in China.
The ﬁndings of this systematic review suggested that
approaches and methods of conducting pharmacoeco-
nomic evaluation are not standardized in China. In
addition, pharmacoeconomic data have not been
widely employed in rational use of drugs and in man-
agement of hospital formulary. Nevertheless, even
though the data of pharmacoeconomic information
have not been adapted as a criterion of decision-
making for reimbursement, increasing number of
pharmaceutical companies in China, especially the
international ones, started using pharmacoeconomic
evaluation as a supportive evidence in the areas of new
drug reimbursement applications, pricing decision,
and marketing approach.
Japan
Health-Care System and Health-Care Financing System
In 1961, the Japanese government established a uni-
versal coverage of health-care insurance for all Japa-
nese, which has played an important role in providing
and maintaining an equal opportunity for people to
access the health-care system in Japan [4].
The Japanese health-care insurance system is
complex with about 5000 insurers classiﬁed into two
broad categories: Employees’ Health Insurance (EHI)
covering 60% of the population, and National Health
Insurance (NHI) for nonemployees, covering the
remaining 40%. A patient holding either an EHI or
NHI card issued by the government is entitled to access
any hospital depending on the needs of the patient.
The accounting and payment of treatment costs,
including drug costs, is performed according to the
fee-for-service (FFS) principle. Patients must contribute
30% of the total expense as a copayment at the point
when a service is provided in a hospital while the rest
is reimbursed to the hospital by the government. The
medical expenditures are determined by the medical-
fee scores and a set of reimbursement rates, which are
uniformly determined and biennially revised by the
Ministry of Health, Labor and Welfare (MHLW) [4].
Despite continuing revisions to maintain the system
under the current ﬁnancing arrangement, the system is
increasingly facing ﬁnancial stress under increasing
demand for better quality of health care from the
population. The major problem comes from the chang-
ing demographic feature of a rapidly aging Japanese
society, which is accelerating the shift of insured from
EHI into NHI. Such a shift makes the NHI ﬁnancially
more vulnerable because of the dual effects of increas-
ing number of elderly population to cover, and a higher
demand for health care for the group relative to the
younger generation. This aging effect of society leads
to a soaring progression over time of national health-
care expenditure, which stood at JPY30 trillion (US
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$250 billion), representing an 8.89% of Japanese GDP
in 2004. The annual rate of increase in health-care
expenditure is approximately 1 trillion JPY (US $8
billions) per year. In addition to the effect of an aging
population, excessive care in practice inappropriately
induced by FFS is another factor contributing to the
increase [5].
Responding to public concerns about soaring
national medical expenditures, former Prime Minister
Koizumi repeatedly reduced medical-fee scores with
decreases of 2.7%, 1.0%, and 3.16% in 2002, 2004,
and 2006, respectively. The latest reductions in
medical-fee scores, by the Koizumi administration, of
3.16% comprised of 1) a reduction of 1.36% of the
“maximal cutoff” of medical service fee since the
implementation of the FFS system in 1961; and 2) a
reduction of 1.8% in fees of medical products, of
which the reduction was 1.6% for drugs and 0.2% for
medical devices. Against this discounting of the
medical-fee scores, the Japan Medical Association
expressed their concerns about a decline in the quality
and safety of health-care services in practice. The claim
is that physicians with less incentive might deliver
inappropriate health care and malpractice, which
eventually decreases the beneﬁt to patients. The other
concerns raised include the following: 1) hospital man-
agers might provide more patients with admission
beyond the capacity of a hospital to save worsening
ﬁnances, consequently; 2) patients might report less
satisfaction of the services delivered because of more
crowded hospitals; 3) competitive capability on busi-
ness of companies might be eroded because of lower
proﬁts; and 4) the government could be too optimistic
for the cost-containment policy in health care.
Regarding the future of improving health ﬁnancing,
three challenging reforms have been implemented by
the MHLW. These include 1) Long-term Care Insur-
ance (LCI) (i.e., Nursing Care Insurance) since 2000;
2) Diagnosis-Procedure Combination (DPC) since
2003; and 3) The Health care Systems Reform Act in
July 2006.
Long-term/nursing care insurance. In the LCI, elderly
people more than 65 years old are insured and sup-
ported with compulsory premium payments by
persons more than 40 years. The features of LCI
include 1) public subsidization with ﬂat rates of
payment by the government according to the grades
(six categories) accredited by the MHLW on the basis
of patient needs; 2) care at home, which would provide
patients with the “beneﬁt” of nursing on-site by
health-care workers; and 3) a “free-to-choose” con-
tract between the insured and a care provider/
company. The objective of LCI launched in 2000 was
not only building a new nursing home system for an
aging society, but also segregating its high-risk ﬁnance
for the elderly from lower-risk ﬁnance in ordinary
health care for younger generations. As anticipated,
ﬁnancial concerns did arise after the launching of the
LCI system, and LCI was subsequently revised in 2005
to make it more robust against increasing costs.
Diagnosis-procedure combination. This is a new case-
mix-based payment (ﬂat payment) program for
diagnosis-procedure combinations of 1860 categories,
based on the ICD-10, for treatment of patients in acute
care in hospitals. After the MHLW introduced the
DPC program in 82 national hospitals in 2003, the
number of hospitals participating in the program
increased to 150 in 2004, and 300 in 2005. The DPC
was intended to shift from the FFS maximizing rev-
enues process of a hospital to a diagnosis-related group
(DRG)-like mechanism minimizing expenditures. Cur-
rently, sufﬁcient evidence is still lacking to evaluate
the cost-saving inﬂuences that could have been caused
by DPC on the national medical expenditures. Never-
theless, it certainly aroused consciousness of cost-
effectiveness in health care, and also the need for
evidence-based or standardized practice employing
clinical pathways. Nevertheless, there are concerns
about declines in quality care, which might be induced
by the ﬂat payment.
The Health care Systems Reform Act in July
2006. This reform aims to achieve three objectives: 1)
prevention against lifestyle-related diseases; 2) imple-
mentation of a new health-care program in 2008 for
elderly people more than 75 years old, with nursing
hospitals downsized from total facilities of 380,000 to
150,000 by the year 2012, with a resultant saving of
about 4 trillion JPY by the year 2025; and 3) re-pricing
of health-care fees downward by 3.16%. Despite this
reform, the government is not optimistic in terms of
the amount of cost-saving. The cost-saving estimated
by the reform is only JPY275 billion per year, although
the medical expenditure would increase by JPY800
billion in the ﬁscal year of 2006 without any reform.
Drug Use and Expenditure
Regarding drug use, the Japanese market is huge with
an annual expenditure of about JPY7 trillion. An
MHLW report estimated JPY7441.8 billion for drugs
in 2004 (US $62 billion). Ninety percent of the sales
(i.e., JPY6737.6 billion) is attributed to pharmaceuti-
cals prescribed in hospitals. The proportion of phar-
maceuticals prescribed in hospitals among all drug
sales increased over time initially from 50% when the
universal coverage of health-care insurance was im-
plemented in 1961. The OECD Health Data 2005
reported the drug expenditure per capita in Japan in
2002 of US $393 (JPY56,592; 1$ = JPY144 in 2002).
For 2004, the drug expenditure per capital is estimated
to be approximately US $484 (JPY58,059; 1$ =
JPY120 in 2004) [6].
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As a proportion of total national health-care expen-
diture, drug expenditure was reported to constitute
23.3% of the total expenditure in 2004 by the MHLW.
In comparison, the market size of generic drugs is only
5.2% in sales and 16.6% in quantity basis, which is
not as large as in the United States, United Kingdom,
or Germany where generic sales are greater than 50%.
Another interesting issue for drug management is the
projection of the drug expenditure after the introduc-
tion of the DPC program in the future. It is estimated
to be more than US $8 billion after all the hospitals
participate in the program, of which about 80% of
the expenditures would be pharmaceuticals including
injections [6].
Drug Management and Pharmacoeconomic Guidelines
Subsequent to the zigzag performance since the 1980s,
the First ISPOR Asia-Paciﬁc Conference in Kobe 2003
opened the door in several Asian countries and pro-
vided the second stage of pharmacoeconomic study in
Japan. To address issues raised at the First ISPOR
Asia-Paciﬁc Conference, the ISPOR Japan Chapter
was established in September 2005. Also, the MHLW
funded a research group to draft the pharmaco-
economic guidelines in 2005 to 2007. The Ministry
of Economy, Trade and Industry (METI), another gov-
ernment entity, expressed an interest in pharmacoeco-
nomics for medical device and diagnostics, and has
organized the Preliminary Committee to develop the
pharmacoeconomic guidelines for medical device and
diagnostics in 2005 with a ﬁrst draft planned for 2008.
There is a substantial need for continuing efforts to
improve how to ﬁnance all sectors of health care in
Japan. Cost reduction becomes the ﬁrst approach;
however, this approach alone may result in a decline of
quality care in Japanese hospitals and communities.
Although the MHLW launched several initiatives for
health-care reform, many professionals in every health
sector recognize a need for new approaches, such
as pharmacoeconomics, to implement sustainable
reform, by shifting the mindset of “health ﬁnance” to
the view of “value-based health care” in Japan.
Role of Pharmacoeconomics
Japan recognizes the key role of pharmacoeconomics
and the value of its related studies in health care at the
early stage of their development. The Japanese Society
for Clinical Economics, which is a renowned entity for
pharmacoeconomic study in Japan, has been estab-
lished for almost 30 years. The key ideas and methods
for pharmacoeconomics were advocated to the stake-
holders in industry and the government in the Interna-
tional Symposium on Clinical Economics, Tokyo,
1988. Responding to the growing interest in such
studies, in the early 1990s, the MHLW recommended
appending pharmacoeconomic data to the dossier for
new drug applications.
Despite the early recognition of the importance for
pharmacoeconomics, in Japan, research and education
in the ﬁeld has not matured enough to build an era of
the use of cost-effectiveness information in health-care
decisions because of skepticism raised from clinicians,
health-care industry, and health-care decision-makers.
Research activities on economic evaluations are still
very limited in Japan, compared to the United States or
Europe [7].
South Korea
Health-Care System and Health-Care Financing System
Korea has undergone remarkable social changes over
the last four decades. The unprecedented high eco-
nomic growth rates from the 1960s through the 1990s
have been accompanied by industrialization, urbaniza-
tion, and most conspicuously, democratization. Along
with these social changes came the development of the
health-care system, which was largely inﬂuenced by
Western medicine. The most noticeable change in the
Korean health-care system was the establishment of
the NHI system. It was implemented in stages over
12 years, and each stage was achieved with little politi-
cal, economic, or social resistance. The expansion of
health insurance coverage toward the whole popula-
tion was a popular issue and received a strong political
support from voters.
NHI is the central organizing mechanism of the
Korean health-care system, through which resources
ﬂow among the government, consumers, corporations,
and service providers, under a relatively weak gover-
nance structure. In most situations, patients are given
a choice of hospitals and clinics. To establish patient
referral channels, regulations were introduced in 1989
to partially restrict the choice of providers available
through the NHI. Nevertheless, the regulations were
not enforced by the hospitals because they feared the
loss of revenues, and most patients do not abide by
these rules.
Providers are paid by FFS for services covered by
the insurance. These fees are paid in part by the
National Health Insurance Corporation (NHIC), and
the rest by patients’ out-of-pocket (OOP) payments.
NHI, in turn, is ﬁnanced by premium contributions
paid by consumers and employers, along with govern-
ment subsidy. The government raises this subsidy
through tax revenues.
The work of health-care delivery is performed
mostly by the private sector. The private sector, which
was dominant in Korea before the insurance plans
were introduced, has grown further with the increase
in per capita income and the expansion of health insur-
ance coverage. Health-care providers are tiered into
general hospitals, local hospitals, and clinics. In 2003,
public local hospitals accounted for only 7% of all
local hospitals, public general hospitals accounted for
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20% of all general hospitals, and clinics are 100%
private. There are 7.1 hospital beds per 1000 Koreans
[8], 87% of which are in private hospitals and clinics
[9].
Drug Use and Expenditure
Development of the modern Korean health-care
system, however, is not without costs. Financial sus-
tainability is under heavy scrutiny at the moment. Sta-
tistics show that total insurance expenditure increased
by about 20% annually from 1993 to 2004 [10],
mostly because of increasing treatment costs. These
increases in treatment costs can be explained by several
factors, some demand-driven and some supply-driven:
expansion of coverage, fee increase greater than the
consumer price index (CPI) increase, population aging,
and aggressive use of new technologies. Nevertheless,
the most important factor has been the use of the FFS
payment method, coupled with nearly unregulated use
of new technologies, which structurally ensures that
the system’s resource requirements are open-ended.
The natural consequence of this is the NHI’s ﬁnancial
deﬁcit (Table 2).
Since 1996, the NHI system had run an annual
deﬁcit each year with the size of the annual deﬁcit
continuously increasing until 2001, which was the ﬁrst
year in which the NHI had a cumulative deﬁcit. A
cumulative deﬁcit was projected in 2003, but it hap-
pened earlier than expected because of the abrupt phy-
sician and pharmacist fee increases at the end of year
2000. The cumulative deﬁcit had made the ﬁnancial
stability of NHI a national priority by the Korean
health authorities. Various actions have been taken to
relieve the deﬁcits including greater government con-
tributions from general tax revenues, higher premi-
ums, a newly introduced cigarette tax, control of fee
increases, and stricter monitoring of medical fraud in
claims processing. The annual deﬁcit signiﬁcantly
declined in 2002, and annual surpluses in both 2003
and 2004 helped to erase the cumulative deﬁcit by the
end of 2004.
There have been speculations and discussions about
the role of pharmaceuticals in this budget instability
phenomenon. Researchers argue that the most contrib-
uting factor toward ﬁnancial unsustainability is the use
of new drugs and the ever-increasing drug expendi-
tures, and as long as the limited management of insur-
gent new medical technologies (equipment, devices,
and drugs) remains as it is, the projected ﬁnancial
sustainability for NHI is somber.
To conﬁrm this argument, a closer look into the
trend of pharmaceutical expenditure was made. The
data reveal that drug expenditure has been rising very
rapidly in Korea. Over the 4-year period of 2001 to
2005, pharmaceutical expenditure in nominal ﬁgures
has nearly doubled, and the real expenditure has
increased by 50%. The issue within the policy arena is
that the rationality of drug expenditure, which
accounts for more than one-quarter of total NHI
expenditures (more than 29% in 2005), has never been
seriously questioned at any level.
From a policy perspective, researchers and policy-
makers point out that the rapidly increased pharma-
ceutical expenditure was probably due to not only so
many drugs are enlisted in the reimbursement list, but
also these new drugs are adopted very quickly in the
Korean market [11]. Early adoption of new entering
drugs could be seen as a problem from the efﬁciency
perspective, as drugs are enlisted in the reimbursement
list with little consideration of budget impacts and/or
cost-effectiveness.
Drug Management and Pharmacoeconomic Guidelines
The NHI Act’s “Guidelines for Determining and
Adjusting New Medical Technologies” stipulates the
use of economic evaluations for decisions regarding
the use of new medical technologies including drugs,
equipment, and diagnosis. Because a signiﬁcant
portion of the increase in NHI expenditure is attribut-
able to the extensive use of new medical technologies,
which are usually cost-increasing rather than cost-
saving, the Ministry of Health and the NHIC are con-
sidering the use of economic data in reimbursement
decisions regarding newly introduced technologies.
The ﬁrst target is pharmaceuticals. For example, at the
moment, almost all drugs that receive market approval
by Korea Food and Drug Administration (KFDA) are
automatically listed as insurance-reimbursed drugs,
Table 2 Trend of national health insurance ﬁnancial status
1993 1994 1995 1996 1997 1998
Revenue 4,116 4,608 5,435 6,326 7,297 7,849
Expenditure 3,363 3,869 5,054 6,413 7,679 8,709
Annual balance 752 739 382 -88 -382 -860
Accumulated surplus 3,432 3,926 4,121 4,002 3,785 3,036
1999 2000 2001 2002 2003 2004
Revenue 8,692 9,529 11,642 13,890 16,823 18,500
Expenditure 9,561 10,538 14,051 14,651 15,744 16,941
Annual balance -869 -1,009 -2,409 -761 1,079 1,599
Accumulated surplus 2,244 919 1,811 2,572 1,492 668
Source: National Health Insurance Corporation, 2005 (unit: billion Korean Won).
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without consideration of their cost-effectiveness and
budget impacts. The result is that over 21,000 drugs
are on the Korean NHI reimbursement list, in stark
contrast to the 3000 to 8000 drugs in the insurance
formulary of most OECD countries. One likely
outcome of having a long list of reimbursable drugs
and many substitutable drugs for one treatment cat-
egory is that many small pharmaceutical companies
will compete heavily for product promotion and
market sales, often using undesirable promotion and
sales strategies, a phenomenon the Korean pharmaceu-
tical market is currently displaying. For example, in an
effort to promote sales, various types of promoting
tools are provided to service providers and pharma-
cists by pharmaceutical companies or wholesalers.
To take the cost-effectiveness and budget impacts of
newly entering drugs into consideration of reimburse-
ment decisions, the Health Insurance Review Agency
(HIRA) recently prepared the Korean version of the
pharmacoeconomic guidelines (KPEG). KPEG pro-
vides pharmaceutical companies with instructions on
how economic data are to be prepared before a drug is
submitted for reimbursement and pricing. Its objective
is to give more consideration to cost-effectiveness
before adopting new drugs into the health insurance
domain.
Use of economic data in reimbursement decisions
can be extended to other technology areas as well,
namely, medical equipment and diagnosis technology.
Nevertheless, how soon and how widely it will be
extended is still undecided, because there are many
stakeholders with strong interests in this issue, both
within and outside Korea; the subject easily becomes
an international trade issue, which is often raised by
medical technology-exporting countries.
Role of Pharmacoeconomics
In using economic data for drug reimbursement deci-
sions, the objective is not to reduce the drug expendi-
tures, the number of drugs in the list (formulary), nor
to reduce drug prices; rather, by using economic data
as a tool in decision-making, the goal is to gain in
rationality in the use of scarce health-care resources.
Like other countries, Korea is in a situation where the
level of resource scarcity is ever increasing with
growing consumer demands and insurgent new
technologies.
Through the practice of emphasizing cost-
effectiveness and rational use of scarce resources, there
is little question that consumers will be better off with
improved access to cost-effective pharmaceuticals.
Population health will also be better in the long run.
For pharmaceutical companies, submitting eco-
nomic data would mean additional ﬁnancial burden
for data preparation and a prolonged period to
obtaining approval for reimbursement decisions.
These could be transmitted as added production costs
to the ﬁrms. Nevertheless, there will be a long-run
efﬁciency gain for the ﬁrms through healthy competi-
tion of price and outcomes (effectiveness) of the prod-
ucts. Over time, producing better product with
improved outcomes through R & D will be the
keyword among the ﬁrms in the industry. The Korean
pharmaceutical industry will be better shaped in the
sense that only efﬁcient ﬁrms survive, and ﬁrms would
rely less on undesirable product advertising and pro-
motion. If the Korean government thinks the growth
of pharmaceutical industry is one strategy for a pros-
perous national economy in the 21st century, use of
economic data for reimbursement decisions would
certainly contribute to such a national goal in the
long run, albeit indirectly so.
By counting the cost-effectiveness of drugs, the
insurance authority ultimately purchases health out-
comes, not products themselves. This is a way to maxi-
mize health outcome for a given set of resource
constraints. Scarce ﬁnancial resources would be allo-
cated more efﬁciently, and rationality of drug expen-
diture would also be enhanced.
Singapore
Health-Care System and Health-Care Financing System
The health-care delivery system in Singapore can be
divided into the public and private sectors, with the
bulk of primary care being delivered through the
private sector, and the bulk of hospital care being
delivered through the public sector health-care
institutes.
The health-care system is ﬁnanced by a mixture of
taxation, compulsory saving through the Medisave
scheme, employee medical beneﬁts, insurance, and
OOP payments. The main principle of the Singaporean
government in maintaining the health-care system is
provision through a balance between the public and
private with a mixture of health-care services. This is
augmented by compulsory savings through the Medis-
ave program, and insurance through the MediShield
program. At the same time, a safety net is available
through the MediFund program for those ﬁnancially
disadvantaged who cannot afford to pay for their
medical expenses with sufﬁcient fund from their
Medisave accounts. A more detailed description of the
operation of the Medisave, MediShield, andMediFund
programs has been previously described [12], and an
update of these programs is described in another pub-
lished article [13]. The fundamental philosophy is
that individuals should have the responsibility to take
care of their own health-care expenditure, but no
citizen should be denied of health care because of
ﬁnancial difﬁculties, and the government is organizing
different measures to help the citizens to achieve these
goals.
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Drug Expenditure, Drug Management, and
Pharmacoeconomic Guidelines
The annual drug expenditure in Singapore is around
SGD 600 million (which is approximately US $375
million). This works out to be US $75 per capita, and
as a proportion of public spending, this constitutes 8%
of public health expenditure.
In the public health-care system in Singapore, drug
management is through the Standard Drug List, which
is maintained by the Ministry of Health (MOH). The
Standard Drug List comprises of two parts, Standard
Drug List 1 and Standard Drug List 2. The difference
between the two lists is that drugs that are included in
the Standard Drug List 1 are heavily subsidized by the
government, while those included in the Standard
Drug List 2 are subsidized at only 50% of the drug
acquisition cost.
No formal pharmacoeconomic guidelines are avail-
able at present, but the concept of cost-effectiveness
has been implicitly applied in the deliberation of
drugs considered for government subsidy through the
public health-care institutes (including polyclinics and
hospitals).
Role of Pharmacoeconomics
The level of awareness and application of pharmaco-
economic information has increased since the last
review was written and published in 2004. Neverthe-
less, because of the nature of the health-care system
and the management philosophy of health care,
progress may not be as quick as researchers in the ﬁeld
would like it to occur. Despite the slower progress,
there are concerted efforts from researchers and
health-care administrators and professionals in pro-
moting pharmacoeconomic research in Singapore.
Throughout the past few years, there have been
several major conferences being organized by local
public health institutes with special themes on cost-
effectiveness in health-care delivery. The latest one was
organized by the SingHealth Postgraduate Medical
Institute in October 2006. In general, these confer-
ences were well attended, with delegates coming from
many different countries in Asia-Paciﬁc and afar. In
addition, there are efforts by the two Singaporean hos-
pital clusters to organize training workshops to equip
their staff in acquiring skills in assessing the cost-
effectiveness of health-care delivery.
In terms of formal training, there is still no formal
accredited courses being conducted locally by the ter-
tiary education institutions to provide specialized
training in pharmacoeconomics. Nevertheless, at the
National University of Singapore, pharmacoeconomic
research is being taught at the introductory level as
part of the pharmacy curriculum. At the graduate
level, there is a very active, although small by staff size,
research group in the department of pharmacy engag-
ing in various aspects of pharmacoeconomic research
in collaboration with various clinical researchers who
have interest in this area of research. The group also
has the capacity to provide consultative services to the
government and pharmaceutical industry in the area
of pharmacoeconomic research. Recently, a Health
Services Research Center has been established at the
National University of Singapore. It is therefore envis-
aged that there will be more resources available to
pursue in research projects in the area in the foresee-
able future. Overall, the capacity and resources avail-
able for pharmacoeconomic research have improved
since we last visited this issue.
Regarding the application and use of pharmacoeco-
nomic research in decision-making, there is a Pharma-
coeconomic Evaluation and Drug Utilization (PEDU)
Unit set up at the Center for Drug Administration,
Health Sciences Authority with funding provided by
the MOH. Any drug that has been put up for consid-
eration for inclusion into the SDL would need to go
through the application process where the evaluators
at the PEDU will provide an abridged report outlining
the cost-effectiveness of such drugs and the ﬁnancial
impact to the governmental drug budget for delibera-
tion by the Drug Advisory Committee (an advisory
body with members from various medical disciplines
and pharmacy, and the membership is by appointment
by the MOH). The use of a relatively simpliﬁed cost-
effectiveness evaluation is really a trade-off considering
the available staff level at the Pharmaceoconomics and
Drug Utilization Unit, and the level of acceptance and
understanding of pharmacoeconomic concepts by the
members of the Drug Advisory Committee. Neverthe-
less, there always exists the option that the Drug
Advisory Committee can request for a more detailed
pharmaceocononmic evaluation to be performed by
the PEDU for speciﬁc drugs.
Thailand
Health-Care System and Health-Care
Financing Systems
Thailand has a pluralistic public and private mixed
system for ﬁnancing and service provision although
public ﬁnancing and provision still plays a dominant
role. Thailand has provided a universal health-care
coverage (UC) through a tax scheme since 2001. The
scheme protects the 45 million population who are
not eligible for Civil Servant Medical Beneﬁt Scheme
(CSMBS), which covers the government and state
enterprise employees and their dependents, or Social
Health Insurance (SHI), which is a mandatory health
insurance for private sector employees in companies
employing more than one employee [14]. As a result,
96% of the total 64 millions of Thai population was
covered by one of these three public insurance
schemes. Table 3 describes the key characteristics of
these major insurance schemes.
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Overall resources devoted to health care have
gradually increased recently. The THE per capita per
year was 2160 baht (US $86) at current year price in
1994, and had increased to 3974 baht (US $98) in
2005 [15]. In 1994, private sources of ﬁnancing played
a major role, 55% of THE. As a result of ﬁnancing
reform, in 2005, public source played the major role;
64% of THE.
Budget constraints in health systems prompt stake-
holders to be rewarded for priority setting [16]. Senior
administrators, hospital directors, and health profes-
sionals have all realized the fact that it is impossible
that the UC beneﬁt package covers all medicines and
interventions available in the market; thus, use of cost-
effectiveness comparisons and rationing is inevitable.
This requires the trust of the public on the application
of a well-structured and evidence-based approach to
generate this information.
Drug Use and Expenditure
Data on drug utilization in Thailand suffer from
incomplete databases. For example, the underreport-
ing by manufacturers and importers to the Thai Food
and Drug Administration (TFDA), the magnitude of
drug distribution through various channels including
self-medication to the end users, and the percentage
markup by these channels are examples of where good
data are lacking. Nevertheless, the best estimate of
total drug expenditure is 36.04% of THE in 2002, or
1152 baht per capita (US $27). Over time, imported
drug products revealed an increasing trend in market
share by sales (Fig. 1) [17].
Health-care services outside the terms and condi-
tions (e.g., bypassing the contracting providers for UC
and SHI members to private hospitals and clinics
including drugs) are subject to full direct payment by
households. In 2004, the monthly household expendi-
ture for self-medication, mostly through private phar-
macies, was 83.6 baht, on average, which is 0.9% of
the total consumption expenditure [18]. Private phar-
macies are licensed by the TFDA for nonprescription,
prescription, and traditional medicines.
The drug beneﬁt for all public insurance schemes
(CSMBS, SHI, and UC schemes) was referenced to the
medicines quoted in the National List of Essential
Medicines (NLEM). A prescription of the nonessential
drug (non-ED) is covered if deemed necessary. The ED
List is periodically updated by a subcommittee of the
Table 3 Health insurance schemes, 2002
Scheme CSMBS SHI
UC
scheme
Year of introduction 1960 1990 2001
Beneﬁciaries Government employees,
dependents, and pensioners
Private sector employees, no
dependents covered
The remaining population who are
not covered by CSMBS and SHI
Population coverage 10% 13% 74%
Source of ﬁnance Government budget,
noncontributory scheme
Tripartite payroll contributions by
employee, employer, and the
government
Government budget (general tax
revenue)
Payment to health facilities FFS reimbursement Capitation inclusive outpatient and
inpatient services
Capitation for outpatient, disease
prevention, and health
promotion services.A global
budget with case- base payment,
i.e., (DRG) for inpatient service
CSMBS, Civil Servant Medical Beneﬁt Scheme; SHI, Social Health Insurance; UC, Universal Coverage; FFS, fee-for-service; DRG, diagnosis-related group.
Figure 1 1983–2002 market penetration of
imported drug products share of total sales.
Source: [17].
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National Drug Committee. The current NLEM
(AD2004 version) has 882 items. Customary, dispens-
ing non-ED list drugs is subject to full pay by any
beneﬁciaries.
In a closed-end provider payment, such as capita-
tion and global budget with DRG in SHI and UC
schemes, the providers have an incentive to dispense
the lower-cost generic products to make a margin from
the capitation. In contrast, empiric evidence indicates
that CSMBS beneﬁciaries were more likely given the
expensive single-source drug products than those
in other schemes [19,20], as CSMBS applies FFS
payment.
On price control, a reference price was applied only
to drug products covered by NLEM, according to the
Procurement Regulation, but only enforced in the
public hospitals when purchasing ED. After the 1997
economic crisis, the Ministry of Public Health “good
health at low cost” policy enforced a mechanism to
purchase drugs at the lowest possible price, given good
quality and standards. Main elements of this policy are
common drug list, collective bargaining, and bulk pur-
chasing at provincial level, although this is not strongly
enforced currently.
Drugs prescribed by private clinics and hospitals
have higher markups. Charges in private pharmacies
are subject to price control by the Ministry of Com-
merce in theory; in practice, however, the manufac-
turer or wholesale price depends largely on market
segmentation and differential classes of trade, whereas
the retail price depends on the competitiveness of the
market.
Drug Management and Pharmacoeconomic Guidelines
Application of new drugs for registration to the TFDA
is governed by the Drug Act, whereby approval is
based on submitted documents on safety and clinical
efﬁcacy [21]. Real-world effectiveness and efﬁciency
are not considered evidence by the TFDA for market
approval, although attempts have been made to
include efﬁciency into the revision of the Drug Act.
Application of drugs to be considered as national
EDs is governed by regulations set by the subcommit-
tee on NLEM revisions under the National Drug Com-
mittee. Presently, Thailand does not have a standard
guideline for conducting health economic evaluation,
and the subcommittee has not yet developed the selec-
tion criteria based on pharmacoeconomic evidence.
Nevertheless, there is an implicit application of cost
and efﬁciency dimensions [22]. For example, all drugs
applying for ED status would be assessed on the fol-
lowing criteria: 1) completeness of clinical information
submitted; 2) evidence on safety; 3) evidence on ease of
administration and related restrictions; 4) evidence on
frequency of drug administration; and 5) evidence on
clinical efﬁcacy. The composite score (0–1) of the ﬁve
criteria would reﬂect the efﬁcacy score of each drug.
Only drugs that pass 50% of these criteria would be
considered by the subcommittee. An Essential Medical
Cost Index (EMCI) is then estimated. This is the ratio
of the cost of drug daily dose and the efﬁcacy score.
This index reﬂects the relative cost and efﬁcacy of each
drug, an implicit score of cost-effectiveness. Other cri-
teria, such as availability of drugs in the market, are
also considered.
Role of Pharmacoeconomics
Given the fact that more people are living longer, the
increasing incidence of chronic noncommunicable dis-
eases (NCDs), and the advancement in health technol-
ogy, particularly pharmaceuticals, the rapid rise in
health-care costs is one of the major policy concerns of
the Thai government. Evidence on cost-effectiveness
generated from pharmacoeconomic assessment is an
important tool for decisions on allocation of scarce
health-care resources. Nevertheless, pharmacoeco-
nomics is a relatively new discipline in Thailand, which
has not yet been widely applied in policy decision.
Current policy dialogues stress the need for institu-
tional capacity strengthening to provide pharmaco-
economic evidence to guide decisions on drug
registrations by TFDA and adoption of drugs into the
ED.
A systematic literature review revealed that there
were very limited economic evaluation studies in Thai-
land, especially compared to countries where eco-
nomic evaluation has been accepted for formal use in
policy decision-making [23]. This review found that
none of these publications address interventions for
the top 20 burden of diseases (BOD) as measured by
disability adjusted life year (DALY) loss [23]. The chal-
lenge is to minimize fragmentation and competition
among research and funding agencies. A comprehen-
sive and systematic approach is required to prioritize
areas for future economic evaluation, e.g., guided by
BOD proﬁles, or areas of controversy in interventions
or clinical practices. Furthermore, in-depth interviews
with policy actors at the national level, hospital direc-
tors, health professionals, and academic found that
there was limited knowledge and understanding of
concepts and applications of economic evaluation, and
lack of training in health economics, with the excep-
tion of the academic group [16], Without an improved
understanding among these partners, the application
and acceptance of economic evaluation to guide deci-
sions is unlikely.
In the past, it was not possible to apply economic
evaluations for setting priority and resource allocation
because of several constraints. These limitations were
due to limited research capacity to generate evidence,
an absence of a national guideline for conducting eco-
nomic evaluation, limited knowledge and understand-
ing on the tools of economic evaluations, and a lack of
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awareness among decision-makers and health profes-
sionals to support economic evaluation.
Nevertheless, given a better understanding of these
limitations and opportunities of an increasing human
capacity and commitments, a medium-term program
for further capacity building and institutionalization
of a national body for HTA was approved by multi-
partners in Thailand with full funding support. It is
hoped that economic evaluations (pharmacoeconom-
ics) would be institutionalized and would better con-
tribute to decision-making. Recently, the government
has decided to invest in a medium-term program on
HTA, namely Health Intervention and Technology
Assessment Program (HITAP), aiming at capacity
building, methodological standard settings, guideline
for economic evaluation, priority setting for HTA and
conducting economic evaluation for interventions,
which address priority BOD, including pharmaceuti-
cals, medical devices, and health promotion and pre-
vention program. This would, at the end, establish the
National Health Technology Institute to meet increas-
ing challenges and guide resources allocation decisions.
Pakistan
Health-Care System and Health-Care Financing System
Pakistan is the sixth largest country in the world on the
basis of population with a projected population of 162
million. One-third of the population lives below the
poverty line (i.e., meaning, they may not have three
meals a day) [24]. The Pakistan government has rec-
ognized the need and has tried to provide for these
people, but lacks funds and infrastructure, and sub-
jected to unstable political environment. Pakistan is an
emerging economy with improving parameters and a
per capita income of more than $700, which may not
reﬂect the true progress that is always offset by the
annual growth rate of more than 2%. The government
of Pakistan has been spending 0.6 to 1.19% of its GDP
and 5.1 to 11.6% of its development expenditure on
health over the last 10 years [25]. It is a developing
country, which is developing from an agriculture-based
to an industry-based economic system. It is this indus-
trial transition that has subjected its population to a
double BOD. The Western world has passed the tran-
sitional stage so that NCDs are the major health
burden over communicable disease (CD) like infec-
tions. Nevertheless, in Pakistan, CDs and NCDs are
both emerging neck and neck simultaneously, and it is
predicted that NCDs will overtake CDs by the early
quarter of this century [26]. Thus, there is a need for
Pakistan to have cost-effective evidence for decision-
making at the central level.
Pakistan’s health policies are being reviewed and
revised by thought leaders from academia, health tech-
nology, and government. The government has already
launched the “National Action Plan” to counter the
emerging epidemic of NCDs. The early results are
promising, but the long-term results need to be
assessed [26].
Because of poor funding and patronage, the govern-
ment health-care facilities at the primary care level are
understaffed, and lacking material and medicines. This
causes a shift of patients to low-quality private clinics
or to the secondary and tertiary care facilities, which
are then inundated with primary care problems, thus
diluting the tertiary care service. This produces a com-
promised health-care delivery system. The present gov-
ernment has realized these issues and has changed the
long-held health ﬁnance system. Pakistan is divided
into four provinces and two federally administered
areas. The central or federal health departments
develop the policies, and the provincial health depart-
ments deliver health care. Previously, the funding
remained with the provincial governments, but now,
the funds have been allocated to the district level gov-
ernments with the result that the funds are being allo-
cated to the community-based programs. Currently,
resources are channeled to tertiary care for treatment
of diseases. Nevertheless, preventive care programs at
the community level may be the answer to the bur-
geoning NCDs such as cardiovascular disease.
Drug Use and Expenditure
Health-care ﬁnances in Pakistan are mostly patient
OOP payments. More than 80% of the THEs are for
drugs. Drug expenditures are large with annual sales
of US $1.2 billion and an annual growth rate of 10%
to 15%. The pharmaceutical industry comprises 411
local and 30 multinational companies, which produce
125 categories of medicines [27]. Ninety-ﬁve percent of
the rawmaterial used in drugmanufactures is imported,
thus adding to the total imported drug expenditures. In
2005, the drug imports were US $257 million, and the
exports were US $50.4 million. The total drug expen-
diture was US $353 million. The local production was
US $1 billion, and the local consumption was the same.
The local drug share was 47% versus 53% share by
multinational companies. There was an increase in the
export of pharmaceuticals of about 17% [28]. The
pharmaceutical industry is robust and developing to
serve the 162million people in the country. A few of the
local drug companies are also exporting to other coun-
tries in the region, and it is time to consider developing
a forum to bring the industry, the academia, and the
government on the same platform to improve meeting
the health needs of the people.
In 1993, prices were deregulated to encourage com-
petition, which resulted in a huge price hike (up to
400% for some). This caused the imposition of a freeze
in prices, which exists even today, but despite the
freeze, drug prices continue to rise. In 1997, the
national drug policy was announced but has yet to
deliver beneﬁts to the people in terms of enhanced
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access to quality-assured EDs [29]. The Drugs Control
Ofﬁce has published the third revision of the National
Essential Drug List (NEDL), which contains 452
drugs. This makes it the largest NEDL in the South
Asian region. The MOH requires that all drugs pur-
chased by health department are on the NEDL [30].
Drug Management and Pharmacoeconomic Guidelines
Drug management and pharmacoeconomic guidelines
currently do not exist in Pakistan. With the situation
described, it seems an important consideration that
Pakistan should use pharmacoeconomics as a tool for
decision-making in the future. Because of paucity of
health resources, it is only prudent that the use of
drugs and devices be evidence-based and economically
viable. As far as research goes, the state of affairs has
been unsatisfactory. There has been a dearth of local
data, which is very much needed for the country.
Despite the Pakistan Medical Research Council
(PMRC) that was created very early after the inception
of Pakistan, there has been little signiﬁcant research
effort. Pakistan has relied mostly on evidence accumu-
lated from foreign sources, which, at times, make the
application to the local populace and demographics
very difﬁcult. Most of the research has been conducted
by generating retrospective statistical data of variable
quality rather than original research. Very few projects
have optimal public health impact. The PMRC has
funds, which go unutilized because of lack of propos-
als and a tedious process of applying. In short, the
atmosphere is not conducive for research as there is a
lack of infrastructure, funding, and academic incen-
tives. Furthermore, data that are available are not pro-
vided to or is not used by the decision-makers in
creating a positive impact on the population. Decisions
are often based on unbalanced anecdotal experience or
skewed by biased selection of the team of decision-
makers. We are currently far from the point where we
can implement pharmacoeconomic guidelines. Never-
theless, with the participation as an active member in
the Asia consortium of ISPOR, the seeds have been
sown, and the will has been mobilized; the results of
which hopefully will be seen in the near future.
Role of Pharmacoeconomic Research
The challenge is to encourage evidence-based practice,
to curb irrational drug prescribing and irresponsible
dispensing in the community, and to control self-
medication and noncompliance by the consumers.
Being a developing economy with poverty as a major
public concern, there is a need to impart knowledge to
make usage of drugs economically efﬁcient. All actions
need to be governed by laws for smooth and harmo-
nious functioning, and laws to regulate drugs need to
be implemented and updated. In doing all of these, the
process needs to be as transparent as possible.
There needs to be an awareness created for the
subject of pharmacoeconomics in the country, espe-
cially at the university level. This will help build capac-
ity through trained manpower. Pharmacoeconomic
research needs to be fast tracked to generate local
economic information, especially original research in
priority areas. Evidence-based educational, manage-
rial, and regulatory interventions are needed. This will
help in developing and strengthening the management/
control of drug expenditures, especially at the local
level. Pakistan is at the infancy of pharmacoeconomics
and needs not only to learn from other countries,
which have developed guidelines, but also countries in
the region, which are developing pharmacoeconomic
infrastructure and guidelines.
Malaysia
Health-Care System and Health Financing System
Malaysia consists of 13 states and a federal territory
covering an area of 330,252 square kilometers. The
population of Malaysia in 2005 was estimated to be
25.6 million with an annual growth rate of 2.1%.
Bumiputra forms 65.1% of the population; Chinese,
26.0%; Indians, 7.7%; and 1.2% others. Sixty-two
percent of the population lives in the urban areas. The
population is relatively young with 32.9% between the
age of 0 to 14 years, 62.9% between 15 and 64 years,
and only 4.2% more than the age of 65 [31].
Public and private sector providers play an impor-
tant role in the provision of health-care services in
Malaysia. In the public sector, the MOH is the main
government agency responsible for providing health-
care services in the country. Other ministries that
also provide health-care services in the countries are
the Ministry of Higher Education, Ministry of Defense
and Ministry of Internal Affairs, and Ministry of
Women, Family, and Community Development. The
health system is highly centralized with most planning
and organization of health services being carried out
centrally.
The lowest level of health services in the hierarchy is
at the district level, each with a population of about
100,000 to 200,000. Every district is served by a
number of rural health units, each covering a popula-
tion of around 50,000. In each rural health unit, there
are two types of health facilities: health centers and
community clinics. There are four types of hospitals in
the public sector under the MOH: district hospitals,
state general hospitals, national referral center and
special institutions, and non-MOH hospitals. The dis-
trict hospitals typically have between 100 and 200
beds, and are normally run by 6 to 10 medical ofﬁcers.
State general hospitals have 500 to 1500 beds. Each
state has one state general hospital except for the state
of Sabah, which has two. These hospitals provide out-
patient and inpatient care in general surgery, pediat-
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rics, medicine, obstetrics and gynecology, and
psychiatry. Services are provided by both specialist and
nonspecialist medical ofﬁcers.
The National Referral Center is the highest level of
hospital in the hierarchy. This hospital has 2800 beds
and is located in Kuala Lumpur. Although it receives
referrals from other parts of the country, especially
for cases which need specialized care not available in
state general hospital, such as neurosurgery and radio-
therapy, it also provides outpatient and inpatient care
for the surrounding population.
There are seven special medical institutions that
provide inpatient services for speciﬁc diseases in the
country: the National Tuberculosis Center, the Hospi-
tal for Leprosy, and ﬁve mental hospitals. Private
health providers in Malaysia can be divided into four
main groups: private practitioners, private hospitals,
private nongovernmental organizations, and practitio-
ners of traditional medicine.
Private practitioners are registered doctors who
provide services through private clinics. Currently,
there are 5642 private general practitioners clinics and
535 private specialist clinics in Malaysia [32]. Private
hospitals are licensed under the Private Hospital Act of
1971 and deﬁned as any private facility with more
than one bed. There were great variations in the size of
the hospitals in the country, ranging from 2 to 406
beds in 2004. The number of private hospital beds
remains stagnant over the past 5 years to about 20%
to 22% of the total hospital beds in the country. Most
of these private hospitals were located in the cities and
in the more developed states of Malaysia. In 2004,
48.4% of all doctors, 54.1% of dentists, and 76.2% of
pharmacists in the country were employed in the
private health sector [33].
It was estimated that the country spent 3.7% of its
GDP on health care in 2004. This ﬁgure is quite low
compared to most developed nations. The government
ﬁnanced most of the resources in health care, spending
58.3% of the total national health expenditure. Private
expenditure accounts for the remaining 41.7% of the
expenditure.
Public health services are ﬁnanced mainly from
taxes on earned income. Other sources of ﬁnancing for
health services are private voluntary insurance, social
security, and user fees. Private voluntary insurance is
gaining popularity now because there is no compul-
sory insurance or NHI in Malaysia yet at the moment.
It is estimated at least one-quarter of the population is
covered by some form of voluntary health insurance
in Malaysia [34]. The government is currently in the
process of establishing the National Health Financing
Scheme. A working committee has been formed, and
the MOH has ofﬁcially announced that the scheme will
be established within the next 2 years [35].
Highly subsidized user fees are charged for inpa-
tient and outpatient services in all public hospitals.
Under the MOH fee schedule, patients are charged
RM 1.00 for treatment in general outpatient clinic,
and RM 5.00 for specialist care in public hospitals.
Services in the health centers of rural health units are
free of charge. Charges for inpatient care are capped at
the maximum of RM 500 per admission in third class
wards of public hospitals.
Drug Use and Expenditure
Data on drug use and expenditure are only available in
the public sector. In 2004, the MOH spent 10.7% or
RM 963 million of its budgets on drugs. Using the
estimates from national health accounts, the national
spending on drugs is about RM 1666 Million. There-
fore, the per capita expenditure in the public sector for
drugs is about US $27. In Malaysia, the drugs provided
to patients in public facilities are highly subsidized.
The cost of drugs is bundled together with the user
fees. For example, in public hospitals, user fees of RM
1 charged to patients includes drugs, consultations,
and basic laboratory investigations. It was estimated
that the actual cost of outpatient treatment in public
hospitals is between RM 20 to RM 25 per visit. In the
private sector, private practitioners provide consulta-
tions and also dispense drugs to patients. Typically,
patients in private clinics were charged between RM
30 and RM 35, which includes drugs and consulta-
tions [36]. Doctors in private clinics usually get more
income by drug dispensing than providing consulta-
tions. Recently, there were calls to remove the dispens-
ing rights from private clinics. Nevertheless, the
Malaysian Medical Association opposed the proposals
on the grounds of patient convenience and inadequate
number of pharmacy outlets in the country [37].
Drug Management and Pharmacoeconomic Guidelines
The Drug Control Authority (DCA) is the agency
responsible for the licensing and registration of all
drugs in the country. Established as an executive body
under the Control of Drugs and Cosmetics Regulations
1984, the agency has the task to ensure the safety,
quality, and efﬁcacy of pharmaceuticals, health, and
personal care products that are marketed in Malaysia.
The National Pharmaceutical Control Bureau of the
MOH serves as the secretariat to the DCA. The bureau
undertakes the daily operations of drugs and cosmetics
registration together with monitoring and surveillance
activities delegated by the DCA.
Under the MOH, drug costs are controlled by
various mechanisms. In the national drug formulary,
drugs are grouped into three categories. List A are very
expensive drugs and are allowed to be prescribed only
by specialists. List B drugs are moderately priced
drugs, which are allowed to be prescribed by medical
doctors only. List C consists of very cheap drugs,
which are allowed to be prescribed by nurses and other
paramedics. The government purchased the drugs cen-
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trally in bulk to reduce the price. Clinical practice
guidelines have been developed for selected groups of
illness in government hospitals to reduce the variations
in drug usage, to control drug costs, and to improve
the quality of care. Since 1995, the MOH established
the HTA Unit, which carries out the evaluation of
expensive technology including pharmaceuticals. Nev-
ertheless, the unit plays only an advisory role and
produces guidelines on the introductions of new drugs.
Lack of trained human resources is the main obstacle
faced by the HTA Unit to function effectively to
control drug costs in the country [38].
Role of Pharmacoeconomics
Pharmacoeconomics and outcomes research is very
new in the country. As other research activities in the
country, the government is the main funding agency.
The Ministry of Science and Innovation provides
research grants under Intensiﬁed Research in Priorities
Area (IRPA) mechanisms for all research areas includ-
ing pharmacoeconomics. Every year, the grants are
open for applications. In public universities and insti-
tutions of higher learning, the Ministry of Higher Edu-
cation provides limited funding under a short-term
grant for academic staff and postgraduate students to
undertake research projects. Research projects carried
out in the country in the area of pharmacoeconomics
were mostly related to clinical trial funded by pharma-
ceutical companies. Drug-costing studies, and studies
on cost-effectiveness and cost beneﬁt are becoming
more popular study types being funded by pharmaceu-
tical companies.
Major obstacles to pharmacoeconomic research in
Malaysia include inadequate funding and trained
human resources. Other limitations in research and
development in Malaysia include the lack of protected
time for researchers in institutes of higher learning and
universities. Limited access to data and information
for research purposes is another challenge faced by the
researchers. Dissemination of research ﬁndings is also
limited by the lack of publication skills among the
researchers, and made worse by the control on publi-
cation by relevant authorities. Another major obstacle
is the inability to turn research output into policy and
practice for a number of reasons including the lack
of skills among policymakers to make full use of re-
search ﬁndings, and the lack of innovations among
policymakers.
India
Health-Care System and Health-Care Financing System
In India, allopathic (western) and complementary and
alternative medicine health-care practices (ayurveda,
unani, siddah, and homeopathy) operate side by side.
Many patients switch from one practice to another
when relief is not adequate. Higher-quality public
health-care system exists only in larger cities, but is
virtually nonexistent in villages. The private health
care, although unaffordable for many, is booming. The
challenge before India is to make health care accessible
for the majority of its people. Allopathic health care has
emerged as one of the largest service sectors in India. In
2004, the national health-care spending equaled about
5.2% of nominal GDP, or about US $34.9 billion.
Health-care spending in India is expected to rise by
12% per annum from 2005 to 2009, and to scale up to
about 5.5% of GDP, or US $60.9 billion, by 2009. As
far as the ratio of doctors and nurses to the population
is concerned, it is 5.9 doctors, 0.8 nurses, and 0.47
midwives for 1000 people, which adds up to 1.86 health
workers for every 1000 people. According to the Union
Ministry of Health and Family Welfare’s Health Infor-
mation of India, the country had 67,576 government
doctors, meaning, each doctor was serving roughly
15,980 people in 2004 [39].
Of the total US $24 million spent on health care
in India, the private sector health-care spending is
approximately 77% of the total amount (US $18,643
million). Of this, 86% is OOP expenditure. Public
sector expenditure is 21% (US $4953 million), and the
external aid accounts for 2% (US $565 million) [40].
The proportion of insurance in health-care ﬁnanc-
ing in India is very low. The extent of coverage as well
as the type of coverage is key issues related to insur-
ance penetration. Only around 10% of the population
is covered through health ﬁnancing schemes. Selection
criteria by suppliers often restrict the poor (and more
likely to be ill) from affordable prepayment schemes.
The voluntary health insurance market, which is esti-
mated at Rs 4 billion (US $86.3 million) currently, is
growing fast. Industry estimates put the ﬁgure at Rs
130 billion (US $2.8 billion) [41].
Drug Management, Expenditure
Pharmacoeconomic Guidelines
The pharmaceutical sector is growing at a rapid pace,
next to the information and technology (IT) sector.
The pharmaceutical sector has grown by about 100
times to about US $10,000 million during the last
15 years. Likewise, pharmaceutical exports have
increased to US $35,000 million. It is estimated that by
2010, the pharmaceutical industry has the potential to
achieve US $20,000 million in formulations, and US
$6,000 in bulk drugs. This rapid growth of pharma-
ceuticals has led to the revision of the National Drug
Policy of 2002 into the National Pharmaceuticals
Policy of 2006 [42].
Because India is a highly populated and vast
country, health is a state subject. Although there is an
NLEM most recently published in 2003, it serves only
as a model list. Each state is developing its drug policy.
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Some of the states have developed policies such as EDs
list, formulary, treatment guidelines, and monitoring
and evaluation system. Nevertheless, the difﬁcult part
is the implementation of the policy in majority of the
states. One state that has succeeded is the state of Delhi
through public–private partnership effort (Delhi
Society for Promotion of Rational Use of Drugs). The
success in other states is meager [43].
Role of Pharmacoeconomics
The role of pharmacoeconomics in India is in infancy
at present, although clinical research organizations are
being formed rapidly. Several multinational pharma-
ceutical companies and research organizations ﬁnd
India a good destination for their studies. The India
Chapter of ISPOR has been formed, but it needs to
develop the platform for pharmacoeconomics. Never-
theless, methodology, training, and initiatives are
needed for its development.
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